Peter Ellmark - Alligator Bioscience Vice President Discovery
| ATORX Stock | SEK 0.56 0.01 1.82% |
President
Dr. Peter Ellmark, Ph.D. was appointed Vice President Discovery at Alligator Bioscience AB effective as of January 1, 2018. He is currently Principal Scientist at Alligator. since 2018.
| Age | 50 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 46 4 65 40 82 00 |
| Web | https://www.alligatorbioscience.se |
Alligator Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.4821) % which means that it has lost $0.4821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0417) %, meaning that it generated substantial loss on money invested by shareholders. Alligator Bioscience's management efficiency ratios could be used to measure how well Alligator Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | PRESIDENT Age | ||
| Kristoffer Hansson | BioInvent International AB | 49 | |
| Christian Kjellman | Hansa Biopharma AB | 56 | |
| David Liberg | Cantargia AB | 46 | |
| EvaMaria Joed | Hansa Biopharma AB | 54 | |
| Lars Thorsson | Cantargia AB | 54 | |
| Lena Winstedt | Hansa Biopharma AB | 54 | |
| Henk Troostwijk | Hansa Biopharma AB | 58 | |
| Liselotte Larsson | Cantargia AB | 60 | |
Management Performance
| Return On Equity | -1.04 | |||
| Return On Asset | -0.48 |
Alligator Bioscience Leadership Team
Elected by the shareholders, the Alligator Bioscience's board of directors comprises two types of representatives: Alligator Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alligator. The board's role is to monitor Alligator Bioscience's management team and ensure that shareholders' interests are well served. Alligator Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alligator Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sumeet MD, Chief Officer | ||
| Malin Carlsson, Ex RD | ||
| Marie Svensson, Chief Officer | ||
| Julie Silber, Director Relations | ||
| Peter Ellmark, Vice President Discovery | ||
| Sren Bregenholt, Chief Officer |
Alligator Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alligator Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.04 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (5.39) % | |||
| Current Valuation | 236.82 M | |||
| Shares Outstanding | 220.58 M | |||
| Shares Owned By Insiders | 51.92 % | |||
| Shares Owned By Institutions | 11.58 % | |||
| Price To Book | 2.57 X | |||
| Price To Sales | 17.76 X | |||
| Revenue | 12.94 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alligator Stock Analysis
When running Alligator Bioscience's price analysis, check to measure Alligator Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alligator Bioscience is operating at the current time. Most of Alligator Bioscience's value examination focuses on studying past and present price action to predict the probability of Alligator Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alligator Bioscience's price. Additionally, you may evaluate how the addition of Alligator Bioscience to your portfolios can decrease your overall portfolio volatility.